Folger Nolan Fleming Douglas Capital Management Inc. Reduces Stock Position in iShares Biotechnology ETF (NASDAQ:IBB)

Folger Nolan Fleming Douglas Capital Management Inc. lessened its holdings in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 2.1% during the fourth quarter, Holdings Channel reports. The firm owned 65,260 shares of the financial services provider’s stock after selling 1,400 shares during the quarter. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in iShares Biotechnology ETF were worth $8,628,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of IBB. Security National Bank of SO Dak lifted its position in shares of iShares Biotechnology ETF by 0.7% in the 2nd quarter. Security National Bank of SO Dak now owns 10,461 shares of the financial services provider’s stock worth $1,436,000 after purchasing an additional 75 shares during the period. SPC Financial Inc. raised its stake in iShares Biotechnology ETF by 2.4% in the third quarter. SPC Financial Inc. now owns 3,265 shares of the financial services provider’s stock worth $475,000 after buying an additional 75 shares in the last quarter. Werba Rubin Papier Wealth Management lifted its holdings in iShares Biotechnology ETF by 2.7% in the third quarter. Werba Rubin Papier Wealth Management now owns 2,918 shares of the financial services provider’s stock worth $425,000 after buying an additional 76 shares during the period. Capital Investment Advisors LLC boosted its position in iShares Biotechnology ETF by 1.0% during the 4th quarter. Capital Investment Advisors LLC now owns 10,449 shares of the financial services provider’s stock valued at $1,381,000 after acquiring an additional 99 shares in the last quarter. Finally, Prairie Wealth Advisors Inc. boosted its position in iShares Biotechnology ETF by 6.0% during the 2nd quarter. Prairie Wealth Advisors Inc. now owns 1,765 shares of the financial services provider’s stock valued at $242,000 after acquiring an additional 100 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ IBB opened at $132.65 on Friday. The stock’s 50 day moving average is $136.62 and its 200 day moving average is $141.77. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a dividend of $0.0624 per share. The ex-dividend date of this dividend was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.